The CNBC-TV18 news ticker on Twitter. The news breaks here first.
Followers: 869,579
-
HDFC Bank insider Sashidar Jagdishan will take the reins from Aditya Puri by the end of October as RBI waves the green flag. CNBC-TV18 broke the story first this morning, stock rallies over 3% Details at 9 pm on India Biz Hour
I’ll leave no stone unturned to carry forward the rich legacy, says Sashidhar Jagdishan, the banker who succeeds Aditya Puri at HDFC Bank
IMF estimates a CA deficit of about 2.5% of GDP financeable over time, says India's external debt moderate vs other emerging market economies, but rollover risks remain elevated in short term
HDFC Bank insider Sashidhar Jagdishan will take reins fm Aditya Puri who calls his successor 'humane, motivational & thorough'. Who is the new CEO? What are his immediate challenges? We deep dive into change of guard. Exclusive excerpts of Aditya Puri at 5 & 7:30 pm
#MarketAtClose | IT stocks slip after US Prez signs executive order to prioritise American workers. Tech Mahindra & HCL Tech among top losers. Market breadth favours advances; advance-decline ratio at 2:1
#MarketAtClose | Godrej Cons falls 1% after co reports Q1 domestic volume growth below ests
#MarketAtClose | Varun Beverages up nearly 5% after earnings; co sees pick-up in demand
#MarketAtClose | Auto stocks move higher on hopes of demand recovery; Maruti up over 3%
#MarketAtClose | Nifty Bank surges 418 points to 21,490 & Midcap index 172 points to 15,640
#MarketAtClose | Reliance contributes over 50% to Nifty’s gains of 204 points today, surges 7% to post the biggest one-day gain in over 3 months
DIPAM Secy says Govt confident in completing BPCL stake sale in current FY. Govt extended BPCL EoI timeline to Sep on requests from interested bidders
#1QWithCNBCTV18 | Jindal Saw Q1 reports net loss at Rs 9.2 cr Vs profit of Rs 131.4 cr on a yearly basis. Revenue slips 46.3% at Rs 1.640.8 cr Vs Rs 3,056.5 cr. EBITDA down 53.6% at Rs 183.9 cr vs Rs 396.5 cr & margin at 11.2% Vs 13% (YoY)
#1QWithCNBCTV18 | Godrej Cons' Q1 profit & revenue slips on a yearly basis but operational revenue & margin see a rise. Co reports one-time gain of Rs 14 cr
#1QWithCNBCTV18 | Godrej Cons' Q1 domestic volume growth at 3% Vs CNBC-TV18 poll of 4-5% growth
#1QWithCNBCTV18 | Godrej Cons Q1 result beats CNBC-TV18 poll with profit of Rs 395 cr, 31% higher than the estimates
#1QWithCNBCTV18 | Godrej Cons Q1 consolidated net profit at Rs 395 cr Vs CNBC-TV18 Poll Of `301 Cr
Sources tell CNBC-TV18, Govt is confident of completing BPCL stake sale in FY21. BPCL EoI timeline extended to September on requests from interested bidders due to COVID-19 pandemic
Sun Pharma launches FluGuard (Favipiravir 200 mg) at price of Rs 35/tablet, for treatment of mild to moderate cases of #COVID19 in India. #Favipiravir is only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate #COVID disease
Lupin gets tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from US FDA to market a generic version of Jardiance tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharma The medication used together with diet and exercise to treat type 2 diabetes
The CNBC-TV18 news ticker on Twitter. The news breaks here first.
Followers: 869,579
Connect with us on social media
